TEE
CYCN icon

Tibra Equities Europe’s Cyclerion Therapeutics CYCN Stock Holding History

Tibra Equities Europe’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-4,250
Closed -$332K – 81
2021
Q2 		$332K Buy
+4,250
New +$266K 0.1% 110

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tibra Equities Europe's CYCN Position: Q3 2021 in Review

Tibra Equities Europe sold out of Cyclerion Therapeutics (CYCN) in Q3 2021, closing a stake of 4,250 shares — an estimated $332K sold.

Tibra Equities Europe first reported a position in CYCN in Q2 2021 and held it in 1 quarter. The position peaked at $332K in Q2 2021. 61 funds tracked by Wall St. Rank hold CYCN as of Q3 2021.

  • Tibra Equities Europe reported no remaining Cyclerion Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tibra Equities Europe sold 4,250 Cyclerion Therapeutics shares in Q3 2021, an estimated $332K.
  • Tibra Equities Europe first reported a position in Cyclerion Therapeutics in Q2 2021 and held it in 1 quarter.
  • Tibra Equities Europe's Cyclerion Therapeutics position peaked at $332K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q3 2021.

Based on Tibra Equities Europe's 13F filing for Q3 2021, filed 15 Nov 2021.